REGULUS THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.27 USD | +1.79% |
|
-9.56% | +77.34% |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Regulus Therapeut...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.27
USD
Average target price
7.25
USD
Spread / Average Target
+219.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +77.34% | 149M | |
| +2.93% | 108B | |
| +8.82% | 105B | |
| +1.08% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B |
- Stock Market
- Equities
- RGLS Stock
- News Regulus Therapeutics Inc.
- Transcript : Regulus Therapeutics Inc., Q1 2022 Earnings Call, May 12, 2022